Hepatitis C in Haemophilia: Time for treatment for all by Makris, M. & Konkle, B.A.
This is a repository copy of Hepatitis C in Haemophilia: Time for treatment for all.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/110419/
Version: Accepted Version
Article:
Makris, M. orcid.org/0000-0001-7622-7939 and Konkle, B.A. (2017) Hepatitis C in 
Haemophilia: Time for treatment for all. Haemophilia, 23 (2). pp. 180-181. ISSN 1351-8216
https://doi.org/10.1111/hae.13183
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 1 
Hepatitis C in Haemophilia: Time for treatment for all 
Makris M (1,2) 
Konkle BA (3) 
 
Addresses: 
1. Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK 
2. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, 
UK 
3. Bloodworks North West and Department of Medicine, Division of Hematology, University of 
Washington, Seattle, WA, USA 
 
 
The infection of tens of thousands of haemophilic individuals with hepatitis C through their 
treatment is one of the largest medical treatment disasters in history. Most of these infections 
occurred before the introduction of viral inactivation of clotting factor concentrates in 1985 and the 
chronic problems of this infection are still with us today. A revolution in the treatment of this 
infection means that eradication of hepatitis C from the haemophilia community is within reach. 
The introduction of clotting factor concentrates prepared from pooled donations of plasma in the 
1960s and 1970s transformed the lives of persons with haemophilia. Since these pools of plasma 
contained up to 30,000 donations, it was almost invariable that recipients of non-virally inactivated 
concentrates were infected with hepatitis C and often with HIV as well. The introduction of viral 
inactivation was highly efficient in destroying the virus so the problem of hepatitis C in haemophilia 
is largely seen in individuals treated with concentrates prior to 1985. Around 15-20% of those 
infected cleared the HCV virus spontaneously (within 6 months of infection) but in the remainder 
chronic infection which virtually never cleared spontaneously ensued(1).  
The problem with chronic HCV is ƚŚĞƉĂƚŝĞŶƚ ?Ɛpropensity to develop liver cancer or liver failure 
decades after infection. Previous cohort studies have shown that up to 20-30% of the infected 
patients develop end stage liver disease(2)(3). Current data reported to the European Haemophilia 
Safety Surveillance (EUHASS) program up to 2015, show that hepatocellular cancer is the 
commonest cancer in patients with haemophilia and liver disease is the commonest cause of death 
in these individuals (personal unpublished information). The mortality data usually report liver 
disease when this was the main cause of death but they hide the problem of morbidity where 
patients with advanced cirrhosis die due to another cause. 
Attempts to eradicate HCV in haemophilia started in 1987 with interferon monotherapy but the 
chance of sustained virological response (ie long term clearance) was less than 10%(4,5). The 
introduction of ribavirin, pegylated interferon, telaprevir and boceprevir led to a stepwise increase in 
clearance of up to 50-70%(6). The problem with these treatments has been the frequency of adverse 
events, the duration of the treatment of up to 1 year and the inconvenient dosing regimens of 
injections and tablets(4,5).  
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A dramatic change in the treatment of HCV is however upon us with multiple new highly effective 
agents such as sofosbuvir, daclatasvir, ledipasvir, simeprevir, ombitasvir, paritaprevir and dasabuvir 
(7). The current interferon-free treatments which are often once daily oral treatments for 8-12 
weeks achieve clearance in excess of 95% with virtually no side effects. As a result most studies of 
HCV treatment nowadays are reporting consistent clearance in over 95% of treated patients (6,8)(9).  
The field is developing so rapidly that 100% clearance with a single tablet taken for 6-8 weeks with 
virtually no side effects and covering all genotypes is now close to reality. For experienced 
haemophilia clinicians and infected patients this major advance in the treatment of HCV can be 
difficult to comprehend and I often wonder whether the treatment can really be that good? The 
answer most certainly appears to be yes. 
The remarkable efficacy of these regimens in patients with bleeding disorders is documented in the 
study of U.S. patients by Walsh et al published in this issue of the journal [10. Walsh C et al].  Only 
one of the 120 treated patients did not have a documented sustained response at 12 weeks. He was 
a treatment-naïve patient with genotype 3 HCV.  Five of five patients with compensated cirrhosis 
and prior treatment responded. The treatment was well tolerated, including in the 22% of patients 
who were HIV positive.  These data confirm that except for patients with uncompensated cirrhosis 
or coinfection with hepatitis B, treatment of hepatitis C in haemophilia patients is highly effective. 
The downside of the HCV treatment is the price which at first appears incredibly high at around 
£40,000  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?per course of treatment (11). Worldwide there are large numbers of 
HCV infected patients and understandably governments view the potential costs of HCV treatment 
with horror. The pharmaceutical industry explains the very high cost of treatment as the result of the 
high development costs and the fact that this is a cure rather than disease suppression, as for HIV, 
where they can continue to make profits from selling the drugs long term. It has been suggested that 
it cannot cost so much to manufacture a drug but this is no longer a relevant issue when it comes to 
the price of drugs. Whilst 50 years ago the price of a drug related to the manufacturing cost, 
nowadays this cost is a tiny component of the price and the pharmaceutical companies state that 
the cost is now largely to cover their investment in research and development. Cynics, however, 
believe that the cost of a drug is determined by the pricing of the last similar drug to appear on the 
market. 
A number of countries have introduced health technology assessments (HTAs) to evaluate all new 
treatments and the HCV therapies are undergoing evaluation. Initial data suggest that health care 
systems are likely to fund these treatments but their introduction is likely to be rationed.  
Unfortunately, none of these HTAs consider the case for haemophilia separately. Persons with 
haemophilia argue that theirs is a special case based on a moral issue since the treatment provided 
by health care systems, resulted in their HCV infection in the first place.  A stronger case can 
however be made on clinical grounds, since firstly the infection has been present for at least 30 
years and thus more likely to progress and secondly there are additional costs in terms of clotting 
factor concentrate to manage the complications of HCV. Once a person with haemophilia develops 
cirrhosis, they bleed more frequently due to reduction in clotting factors which are all made in the 
liver as well as due to thrombocytopenia secondary to portal hypertension. Every time a patient with 
haemophilia has an endoscopy to look for and treat oesophageal varices or perform a paracentesis 
to examine for spontaneous bacterial peritonitis, there will be an additional financial cost for the 
concentrate to normalise the clotting and thus cover the procedure. Although initially the one-off 
cost of HCV eradication of £40,000 appears high, this is relatively small in comparison to the ongoing 
annual costs of severe haemophilia where the concentrate is often in excess of £100,000 per year. 
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Another concern with the high cost drugs is that most of the world population lives in less affluent 
countries which are unlikely to be able to afford them. Pharmaceutical manufacturers cognisant of 
the criticisms of their pricing, have come up with methods to make the drugs more affordable and 
available in poorer countries. Examples of such schemes include the provision of the anti-HCV drug 
free of charge to every person in the country of Georgia as a test case to see if it is possible to 
eliminate HCV from a whole country and the supply of the drug at a great discount to Egypt where 
10 million HCV patients reside(12). 
Our aim as a haemophilia community should be to eradicate HCV from every infected individual as 
early as possible and thus to avoid the ongoing and constant complications of this pernicious 
infection. Where access is initially rationed, it should be possible to prioritise on the basis of likely 
progression using non-invasive imaging with instruments such as the fibroscan. Individuals with 
cirrhosis and significant fibrosis should be prioritised for treatment but ultimately all persons should 
be treated irrespective of their degree of fibrosis or liver function disturbance.  
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